(Q41666470)

6 October 2017

title

Neuropharmacology of progressive myoclonus epilepsy: response to 5-hydroxy-L-tryptophan (English)

1 reference

progressive myoclonus epilepsy

6 October 2017

1 reference

1 reference

Pranzatelli MR

1

1 reference

6 October 2017

Tate E

2

1 reference

6 October 2017

Huang Y

3

1 reference

6 October 2017

Haas RH

4

1 reference

6 October 2017

Bodensteiner J

5

1 reference

6 October 2017

Ashwal S

6

1 reference

6 October 2017

Franz D

7

1 reference

6 October 2017

publication date

1 August 1995

1 reference

6 October 2017

1 reference

6 October 2017

volume

36

1 reference

6 October 2017

issue

8

1 reference

6 October 2017

page(s)

783-791

1 reference

Amines, anticonvulsants, and epilepsy

6 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.1995.TB01615.X

Monoamine metabolites in lumbar CSF: the question of their origin in relation to clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.1995.TB01615.X

L-5-hydroxytryptophan in treatment of several different syndromes in which myoclonus is prominent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.1995.TB01615.X

Plasma and cerebrospinal fluid neurochemical pattern in Menkes disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.1995.TB01615.X

Mesolimbic dopamine lesions produce an augmented behavioral response to enkephalin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.1995.TB01615.X

L-5-hydroxytryptophan. Correlation between anticonvulsant effect and increases in levels of 5-hydroxyindoles in plasma and brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.1995.TB01615.X

Human pharmacokinetics of long term 5-hydroxytryptophan combined with decarboxylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.1995.TB01615.X

Release of [3H]dopamine byl-5-hydroxytryptophan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.1995.TB01615.X

Serotonin and human myoclonus. Rationale for the use of serotonin receptor agonists and antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.1995.TB01615.X

Reduced cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in children with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.1995.TB01615.X

Correlations between aminergic metabolites simultaneously obtained from human CSF and brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.1995.TB01615.X

Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan. A double-blind study with quantified data processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.1995.TB01615.X

Kinetics of l-5-hydroxytryptophan in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.1995.TB01615.X

Neurochemical analysis of cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.1995.TB01615.X

Classification of progressive myoclonus epilepsies and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1528-1157.1995.TB01615.X

10.1111/J.1528-1157.1995.TB01615.X

21 January 2018

Identifiers

DOI

1 reference

6 October 2017

1 reference